OccuRx Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10M

  • Investors
  • 4

OccuRx General Information

Description

Developer of therapeutic strategies designed to aid in the treatment of disorders associated with retinal fibrosis. The company's strategies offer proprietary small-molecule drugs to address the unmet clinical need for targeted ocular therapies to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye diseases, enabling healthcare professionals to prevent the growth of new and abnormal blood vessels and reduce inflammation of the neurons in the retina.

Contact Information

Website
www.occurx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Corporate Office
  • 31 Queen Street
  • Level 9
  • Melbourne, Victoria 3000
  • Australia
+61 (03) 0000 0000

OccuRx Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OccuRx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 05-Sep-2022 $10M 000.00 Completed Clinical Trials - Phase 2
3. Grant 20-Jul-2022 00.000 00.000 Completed Clinical Trials - Phase 2
2. Seed Round 19-May-2015 $5.13M $5.13M Completed Startup
1. Angel (individual) Completed Startup
To view OccuRx’s complete valuation and funding history, request access »

OccuRx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of therapeutic strategies designed to aid in the treatment of disorders associated with retinal fibrosis. The
Biotechnology
Melbourne, Australia
5 As of 2021
000.00
0000000000 0 000.00

000000

scing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. U
0000000000000
Alpharetta, GA
00 As of 0000
00000
00000000 00000

000000

citation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irur
0000000000000
Redwood City, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OccuRx Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Clearside Biomedical Formerly VC-backed Alpharetta, GA 00 00000 00000000 00000
Adverum Biotechnologies Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
Aileron Therapeutics Formerly VC-backed Boston, MA 0 00000 000000000 00000
Gradalis Private Equity-Backed Carrollton, TX 00 000.00 00000000000 000.00
EyePoint Pharmaceuticals Corporation Watertown, MA 000 00000 00000000 00000
You’re viewing 5 of 9 competitors. Get the full list »

OccuRx Patents

OccuRx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3213293-A1 Compounds for the treatment of disorders and salts and polymorphs thereof Pending 17-Mar-2021 0000000000
AU-2022238294-A1 Compounds for the treatment of disorders and salts and polymorphs thereof Pending 17-Mar-2021 0000000000
EP-4308541-A1 Compounds for the treatment of disorders and salts and polymorphs thereof Pending 17-Mar-2021 0000000000
AU-2020901858-A0 Compounds and methods for the treatment of eye disorders Pending 05-Jun-2020
AU-2020901856-A0 Compounds and methods for the treatment of eye disorders Pending 05-Jun-2020
To view OccuRx’s complete patent history, request access »

OccuRx Executive Team (6)

Name Title Board Seat Contact Info
Darren Kelly Ph.D Founder, Chief Executive Officer, Managing Director & Executive Chairman
Michelle Bradney Ph.D Chief Operating Officer
Fay Khong Ph.D Senior Associate, Research & Commercialisation
Gareth Lewis Ph.D Chief Commercial Officer
You’re viewing 4 of 6 executive team members. Get the full list »

OccuRx Board Members (3)

Name Representing Role Since
Christopher Nave Ph.D Brandon Capital Chairman 000 0000
Darren Kelly Ph.D OccuRx Founder, Chief Executive Officer, Managing Director & Executive Chairman 000 0000
John Kurek Ph.D Uniseed Board Member 000 0000
To view OccuRx’s complete board members history, request access »

OccuRx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OccuRx Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brandon Biocatalyst Venture Capital Minority 000 0000 000000 0
Brandon Capital Venture Capital Minority 000 0000 000000 0
Stoic Venture Capital Venture Capital Minority 000 0000 000000 0
Uniseed Venture Capital Minority 000 0000 000000 0
To view OccuRx’s complete investors history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »